Mar
18
Posted under
BIO Europe,
Blog,
Companies,
Deals,
Diagnostics,
Funding,
Inside BIO Industry Analysis,
Medical Devices,
Medical Supply,
opening remarks,
orphan,
Partnering,
Partnering Stats,
Pharmaceuticals,
PRIVATE BIOTECH,
PUBLIC BIOTECH - Stats,
PUBLIC BIOTECH - Stock performance,
public sector research,
Startups,
Universities,
venture capital,
venture financing,
venture funding,
Videos by biotechnow@bio.org (Biotechnology Industry Organization)
For Monday’s Opening Remarks at BIO Europe Spring 2012, I covered the following topics:
- Public market performance in the US vs other sectors
- Private funding environment.
- Drug pipeline deal volume.
For a copy of the slides, they can be found here.
Mar
18
Posted under
BIO Europe,
Blog,
Companies,
Deals,
Diagnostics,
Funding,
Inside BIO Industry Analysis,
Medical Devices,
Medical Supply,
orphan,
Partnering,
Partnering Stats,
Pharmaceuticals,
PRIVATE BIOTECH,
PUBLIC BIOTECH - Stats,
PUBLIC BIOTECH - Stock performance,
public sector research,
Startups,
Universities,
venture capital,
venture funding,
Videos by biotechnow@bio.org (Biotechnology Industry Organization)
For Monday’s Opening Remarks at BIO Europe Spring 2012, I covered the following topics:
- Public market performance in the US vs other sectors
- Private funding environment.
- Drug pipeline deal volume.
For a copy of the slides, they can be found here.
Mar
13
Posted under
biotech industry,
Biotechnology Industry,
Blog,
Business and Investments,
Companies,
Diagnostics,
Funding,
industry trends,
Inside BIO Industry Analysis,
IPO,
Medical Devices,
Medical Supply,
Pharmaceuticals,
PUBLIC BIOTECH - Stats,
PUBLIC BIOTECH - Stock performance,
Startups,
Universities,
Videos by biotechnow@bio.org (Biotechnology Industry Organization)
According to Mark Twain, “History does not repeat itself, but it does rhyme”. Little did he know that one day that would hold true for something called “Biotech”. Indeed, there seems to be a lot of rhyming going on with Biotech IPOs today with recent history.
When we compare the accumulated number of IPOs in the last IPO window (2003-2007) with the current window (2009-now), we see an amazing overlay. Not identical, but not too far from it. As of March 2012, we have 34 IPOs. That compares to 33 back in March 2006:
If this continues through 2012, we will add 12 more IPOs over the next three quarters, for a grand total of 46 IPOs since 2009. Then in 2013, we would need to see 20 more to reach the final 2007 goal of 66 IPOs.
After that, let’s hope Twain’s observations no longer hold true, and we don’t repeat 2008.
Jan
12
Posted under
2011,
biotech industry,
Blog,
CEO,
Companies,
Diagnostics,
Funding,
index,
Inside BIO Industry Analysis,
Medical Devices,
Medical Supply,
Pharmaceuticals,
PUBLIC BIOTECH - Stats,
Startups,
stocks,
Universities,
Videos by biotechnow@bio.org (Biotechnology Industry Organization)
How did the Nasdaq Biotechnology Index (NBI) perform in 2011 relative to other sectors?
Second place. Not so bad considering 2011 was the year of defense in the stock market. Like a page out of a textbook on defensive market plays, utilities edged out ahead with a +15% gain, followed by consumer staples with 11%. The NBI squeezed in between at 12%, just above the overall healthcare sector.
Overall, the S&P500 was flat for the year, so the NBI took home double digit alpha for 2011. However, it was not an easy ride for either as this next chart shows. That big drop in August (the AAA crash) meant a -22% drawdown for the NBI (in red below) and -16% for the S&P500 (in black). The big pop in the spring was in part due to data coming out of Biogen Idec, Pharmasset, and Regeneron, and approval hopes for Vertex. The December pop was a Christmas gift from GILD.
It is also useful to compare the NBI vs the Russell 2000 Small Cap index, given that most biotechs are small caps. The movement of Russell 2000 will give you a better idea of what your typical biotech may have experienced in 2011. (The NBI really shows you the movement of large and mid cap companies, which account for 78% of the market value of the index. It can be hard to imagine this given that 75% of the companies in the NBI are actually small caps. It is just that they comprise such a small weighting.) Below is a month by month breakdown of performance for the Russell 2000. Note the big swing the Russell 2000 took from September to October. The NBI held up (relatively speaking) and avoided ending up in the red for the year. The “R2″ left 2011 down -6%.
Next time we will look at the Amex Biotech Index (BTK) performance in 2011. The BTK was actually down -16%, but why?…
